Atu027: Completed Phase Ib/IIa enrollment

Silence said it completed enrollment of 24 patients with locally advanced or metastatic pancreatic adenocarcinoma in the Phase IIa portion of an open-label, German Phase Ib/IIa trial of Atu027 plus ge...